Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990;110(3-4):165-77.
doi: 10.1007/BF01311286.

Colonization of adrenal glands and ovaries of mice by HSV-2 variants. I. Virological studies

Affiliations

Colonization of adrenal glands and ovaries of mice by HSV-2 variants. I. Virological studies

J Podlech et al. Arch Virol. 1990.

Abstract

HSV-2 strain ER was shown to consist of variants with different pathogenic phenotype: Variant ER+ replicates to high titers in the adrenal glands and the ovaries but much less in the spleen; the testes were not colonized. ER+ migrates to the spinal ganglia and is highly neuroinvasive after i.p. inoculation. Variant ER- replicates 100-1,000 fold less in the adrenal glands and the ovaries, but proceeds to the spinal ganglia without invading the CNS. However, both variants are highly neuropathogenic after direct i.c. injection. We conclude that neuropathogenicity, neuroinvasiveness and the ability to replicate in the adrenal glands as well as ovaries are each determined by different sets of genes. Replication in mouse embryo fibroblasts--but not in Vero and adreno cortical carcinoma Y1 cells--is different for both strains. Also the adsorption capacity to cultured cells differs as shown by addition of D.S. 500. ER- is eliminated from the blood stream more quickly than ER+. Finally, C. parvum reduces the rate of replication of both variants in the adrenal and the ovaries. It is concluded that different adsorption and replications rates of variants ER+ and ER- in cell types critical for spread of HSV are responsible for the different pathobiological properties.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer Immunol Immunother. 1988;27(2):128-32 - PubMed
    1. J Immunol. 1970 May;104(5):1155-9 - PubMed
    1. Infect Immun. 1977 Apr;16(1):9-11 - PubMed
    1. Arch Virol. 1980;65(3-4):219-27 - PubMed
    1. J Gen Virol. 1982 May;60(Pt 1):25-9 - PubMed

MeSH terms

Substances

LinkOut - more resources